Entity family

Browse funders

Organisations named as supporting, sponsoring, or funding research. Examples include Wellcome, NIHR, research councils.

14articles mentioning funders

15funder mentions

1distinct funders extracted

0%of mentions human-reviewed

Active filtersEntity: GSK ×

GSK

This funder is selected. Its supporting articles are shown below.

Articles mentioning GSK

14 articles · page 1 of 2

5-019 Herpes zoster incidence rates in adults aged 18 years or older with coronary artery disease or heart failure in England: a retrospective cohort study using data from the clinical practice research datalink (2012–2019)

heartjnl · abstract · 2025-08-13 · 2 matching annotations

90.1%

GSK Herpes Zoster Coronary Artery Disease

…s, clinical guidelines and immunisation recommendations.Funding GSK (VEO-000562).Abstract 5-019 Table 1Baseline characteristics of …

Belimumab induces early and sustained resolution of lupus thrombocytopenia

lupusscimed · abstract · 2026-06-17 · 1 matching annotations

95.5%

GSK belimumab belimumab-treated SLE leucopenia

…omised controlled clinical trials of belimumab were provided by GSK. These datasets included 1769 patients treated with belimumab a…

P.113 Heterogeneity in treatment outcomes for systemic sclerosis with or without interstitial lung disease: a systematic literature review

jsrd · abstract · 2026-06-05 · 1 matching annotations

88.8%

GSK GSK belimumab SSc-ILD Systemic sclerosis (SSc)United States National Institutes of Health Clinical Trial Registry American College of Rheumatology interstitial lung disease (ILD)ACR

…this trial in the context of the clinical evidence base.Funding GSK (GSK Study 219961).Abstract P.113 Table 1Study eligibility crit…

OP13 Belantamab-mafodotin keratopathy: what it is and what ophthalmologists need to do

bmjophth · abstract · 2026-04-29 · 1 matching annotations

89.0%

NICE FDA GSK multiple myeloma Belantamab-mafodotin UCL Hospital Belamaf bilateral microcystic epithelial keratopathy

…ologic for multiple myeloma which has been recently approved by NICE in the UK and FDA in the USA. In Moorfields we have been seeing…

PO:11:295 Predictors of real-world remission in patients with SLE initiating belimumab in the USA

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

81.4%

GSK GSK belimumab SLE standard therapy

…ving remission; this retrospective, observational cohort study (GSK Study 222161) explored predictors of remission in this patient …

PO:11:297 Kidney function preservation with belimumab in patients with lupus nephritis receiving MMF standard therapy in BLISS-LN: improved proteinuria, clinical outcomes and biomarkers for belimumab vs placebo

lupusscimed · abstract · 2026-03-01 · 1 matching annotations

94.3%

GSK LN SLE Belimumab cyclophosphamide mycophenolate mofetil BLISS-LN CYC BEL MMF

…tion maintenance data to support LN treatment decisions.Funding GSK (BEL114054, NCT01639339)Original presentation: ASN 2025…

42 Baseline systemic immune mediators and tumor microenvironment features associated with disease outcomes in colon cancer

jitc · abstract · 2025-11-04 · 1 matching annotations

86.1%

FAPESP Trust in Science GSK colon cancer CC immunotherapy

…matory axes in high-risk patients.Acknowledgements Supported by FAPESP (grant numbers #21/00408-6; 2024/10964-1), GSK, and Trust in Sc…

P118 Understanding the experience and unmet needs of patients living with severe asthma on biologic therapy; including views on clinical remission

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

91.8%

GSK severe asthma SA biologic therapies Ipsos

…rapy and identified perceived gaps in care.Methods On behalf of GSK, Ipsos conducted a 10-minute online survey among 100 UK adults …

P2 Disease stability, management and treatment goals in chronic obstructive pulmonary disease among newly diagnosed vs long-term diagnosed patients: a patient survey

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

92.8%

GSK COPD COPD-specific asthma hypertension LD ND

…nt-centred approach to disease management and stability.Funding GSK…

S135 Twice-yearly depemokimab demonstrates efficacy in patients with asthma across baseline medium- and high-dose ICS subgroups: Phase III SWIFT-1/2 studies

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

96.9%

GSK NCT04719832 NCT04718103 Depemokimab asthma St George's Respiratory Questionnaire

…supporting potential initiation prior to ICS escalation.Funding GSK (206713/213744; NCT04719832/NCT04718103).Abstract S135 Figure 1…

S164 Mepolizumab improves and sustains asthma control and lung function in patients with severe asthma, independent of baseline IgE and FeNO in the real world: 2-year results from REALITI-A

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

94.3%

GSK 204710 mepolizumab severe asthma Asthma

…tained to 2-years, independent of baseline FeNO and IgE.Funding GSK (204710).…

T5 Reduced airway remodelling and increased epithelial barrier integrity in bronchial biopsies from patients with T2 high severe asthma following mepolizumab treatment

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

94.0%

GSK mepolizumab T2 high SA T2 high severe asthma NCT05144087

…T0) and 6 months (T6) post mepolizumab treatment ( NCT05144087, GSK funded, investigator led study). Fourteen (70%) paired biopsies…